[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-tract-infection-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-tract-infection-diagnosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,39,75,85,109,138,164,196,223,250],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100054205","chronic-radiation-cystitis-and-effect-of-hyperbaric-oxygen-therapy-on-patient-reported-outcomes-and-urine-inflammatory-biomarkers-100054205",false,"NCT07368647","Chronic Radiation Cystitis and Effect of Hyperbaric Oxygen Therapy on Patient Reported Outcomes and Urine Inflammatory Biomarkers","Inclusion Criteria:\n\nCohort 1\n\n* At least 18 years of age\n* Post pelvic radiation carrying the diagnosis of moderate to severe radiation cystitis and recurrent macroscopic hematuria in the absence of infection or urothelial malignancy. The diagnosis of moderate to severe (Radiation Therapy Oncology Group (RTOG) grade 2, 3-4) RC will be made by board-certified, reconstructive Urologists routinely managing radiation cystitis patients in their practices (RM \u002FWB,III) or co-investigator (JB) using Appendix B and confirmed with cystoscopy and negative urine cytology and\u002For bladder biopsy to rule out malignancy (which is standard of care of work up of hematuria as defined by the American Urology Association)45 once all other pathologies for gross hematuria have been excluded (including infection, malignancy, etc).\n* Scheduled to, or currently undergoing (initiated within the past 7 days), HBOT as part of standard of care therapy for radiation cystitis Cohort 2 HBOT controls\n* At least 18 years of age\n* Without a history of prior pelvic radiation\n* Scheduled to, or currently undergoing (initiated within the past 7 days) HBOT as part of standard of care therapy for reasons that do not include bladder inflammation) Cohort 3 Healthy controls\n* At least 18 years of age\n* Without history of pelvic radiation or HBOT Cohort 4\n* At least 18 years of age\n* Same as Cohort 1 except they OPT-OUT of participation in HBO therapy.\n\nExclusion Criteria:\n\nAll Cohorts\n\n* Pregnant or lactating (females will be asked if there is any chance they could be pregnant).\n* Uncompensated heart failure, uncompensated fluid overload, or uncompensated myocardial infarction preventing therapeutic HBOT\n* A history of: uncontrolled seizure disorder, active urinary tract infection, active Grave's disease, cystic fibrosis, sickle cell anemia, known HIV, or any autoimmune disease not in remission that requires active systemic steroid therapy or immune modulating medications.\n* Refusal to sign IRB approved informed consent document\n* Prior participation in a clinical trial that could potentially affect immunological status",true,"ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Collection of urine, blood, and tissue samples from patients undergoing hyperbaric oxygen therapy",[24,25],"Radiation Cystitis","Urinary Tract Infection (Diagnosis)","RECRUITING","2026-07-09",{"date":29,"type":30},"2026-07-13","ACTUAL",{"date":32,"type":30},"2022-04-04",{"date":34,"type":20},"2027-12",{"name":36,"class":37},"Rachel A. Moses","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":49,"conditions":50,"keywords":57,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100603302","febrile-infants-swedish-study-100603302","NCT07134751","Febrile Infants Swedish Study","FISS","Inclusion Criteria:\n\n* Temperature ≥38.0 C (measured either at home or at the pediatric emergency department)\n* Age ≤60 days","60 Days",{"count":48,"type":20},2000,"Approximately one million febrile infants aged ≤60 days present annually to pediatric emergency departments (PEDs) in Europe and the United States. Although fewer than 5% are diagnosed with meningitis or bacteremia (invasive bacterial infections - IBIs), and 10-15% with urinary tract infections (UTIs), current guidelines recommend extensive diagnostic evaluations, hospitalization, and empirical treatment with broad-spectrum parenteral antibiotics. This approach may contribute to medical overuse, with implications for patient care, healthcare resource utilization, and environmental sustainability.\n\nThe Febrile Infants Swedish Study (FISS) is a prospective observational study conducted across 11 PEDs in Sweden. All febrile infants aged ≤60 days presenting to participating sites will be eligible. A new clinical guideline for the management of infants with fever without source (FWS) will be implemented in 7 PEDs, while 4 PEDs will continue with current standard practice and serve as a comparison group.\n\nThe study is expected to run for approximately two years and aims to recruit a minimum of 2,500 febrile infants",[51,52,25,53,54,55,56],"Febrile Illness Acute","Meningitis, Bacterial","Invasive Bacterial Infection","Serious Bacterial Infection","Bacteremia","Sepsis",[58,59,60,61,62,63,64],"Guidelines","Febrile infants","Age ≤60 days","Management","Serious Bacterial Infections","Invansive Bacterial Infections","Clinical prediction tool","2026-04-01",{"date":67,"type":30},"2026-04-02",{"date":69,"type":30},"2025-12-01",{"date":71,"type":20},"2028-09-30",{"name":73,"class":37},"Region Skane",11,{"id":76,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":78,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":84,"locationsCount":38},"100621286",{"count":19,"type":20},[24,25],"2026-01-20",{"date":81,"type":30},"2026-01-26",{"date":32,"type":30},{"date":34,"type":20},{"name":36,"class":37},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":38},"100616684","early-phase-1-intravesical-lactobacillus-crispatus-clinical-safety-and-microbiome-evaluation-100616684","NCT07308808","Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation","Inclusion Criteria:\n\n* Age ≥ 18 years\n* SCI with at least 6-month duration\n* NLUTD\n* Utilizing intermittent catheterization for bladder management\n* Community dwelling\n\nExclusion Criteria:\n\n* Use of prophylactic antibiotics\n* Instillation of intravesical antimicrobials to prevent UTI\n* Psychological or psychiatric conditions influencing the ability to follow instructions\n* Use of oral or IV antibiotics in the past 2 weeks\n* Pregnancy\n* Known genitourinary pathology beyond NLUTD\n* Participation in another study that could confound results of the proposed study",{"count":92,"type":20},40,"INTERVENTIONAL",[95],"EARLY_PHASE1","The goal of this clinical trial is to determine whether Lactobacillus crispatus strains isolated from the lower urinary tracts of adult women can be used as an antibiotic-sparing treatment for urinary symptoms and urinary tract infection (UTI) among adults with neurogenic lower urinary tract dysfunction (NLUTD). The main question\\[s\\] it aims to answer are:\n\n1. To identify soluble bactericidal compounds produced by urinary isolates of L. crispatus that kill uropathogenic E. coli (UPEC).\n2. To determine if intravesical instillation of L. crispatus is safe and well tolerated in adults with NLUTD due to SCI who use intermittent catheterization (IC).\n\nIf there is a comparison group: Researchers will compare L. Crispatus to standard care saline to see if there is a difference in urinary symptoms and urinary microbiome.\n\nParticipants will be asked to complete daily symptom surveys, complete 2 bladder instillations, and collect, freeze, and return 14 urine samples.",[98,99,25],"Spinal Cord Injuries (SCI)","Neurogenic Bladder","2025-12-22",{"date":102,"type":30},"2025-12-30",{"date":104,"type":30},"2025-09-09",{"date":106,"type":20},"2027-03-30",{"name":108,"class":37},"Medstar Health Research Institute",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":38},"100584998","urinary-infection-and-colonization-in-bone-procedures-100584998","NCT06896643","Urinary Infection and Colonization in Bone Procedures","Inclusion Criteria:\n\n* Age over 65 years, including\n* Elective or acute trauma\u002Forthopedic bone surgery\n* Urine examination as part of pre-anesthetic examination, urine + sediment, in case of suspicion - bacteriological examination\n* Signed informed consent for research as part of pre-anesthetic examination (I or II), respecting informed consent as an expression of the patient's \"free will\"\n\nExclusion Criteria:\n\n* Negative finding in urine: chemical examination + sediment preoperatively\n* Respondent under the influence of premedication, alcohol, or drugs\n* Sensory impairment (blindness)\n* Delirious preoperative state\n* Severe mental disorder\n* Sopor\n* coma\n* Septic state\n* Acute respiratory failure\n* Disagreement with participation in the study","65 Years",{"count":117,"type":20},80,"For seniors aged 65 and over (inclusive) undergoing surgical procedures (bone surgery, traumatology, orthopedics) in an acute or elective setting, the relationship between preoperative urinary tract infection\u002Fcolonization (within 30 days before the procedure) and the occurrence of predefined postoperative complications (monitoring during the patients' hospitalization) will be observed",[120,121,25,122],"Urinary Tract Infection","Complications","Frailty",[124,125,126,127,128],"urinary","tract","infection","colonization","postoperative complications","2025-07-06",{"date":131,"type":30},"2025-07-08",{"date":133,"type":30},"2025-06-01",{"date":135,"type":20},"2026-06-01",{"name":137,"class":37},"Tomas Bata Hospital, Czech Republic",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":15,"sex":144,"minAge":17,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":38},"100590071","association-of-urinary-tract-infection-with-preeclampsia-during-pregnancy-100590071","NCT06962644","Association of Urinary Tract Infection With Preeclampsia During Pregnancy","Inclusion Criteria:\n\n* Patients attending OPD for routine antenatal checkup\n* Patients diagnosed with UTI as per operational definitions\n* Gestational age greater than 20 weeks as per LMP\n* Age between 18 to 35 years\n\nExclusion Criteria:\n\n* History of medical conditions such as:\n* Diabetes mellitus\n* Chronic hypertension\n* Chronic liver or kidney diseases\n* Chronic pulmonary conditions\n* History of urological surgical interventions in the past 3 months\n* History of renal transplants\n* Patients on immunosuppressive therapy\n* History of comorbid conditions including:\n* Diabetes mellitus\n* Gestational diabetes mellitus\n* Hypertension\n* Chronic hepatic diseases\n* Chronic liver diseases\n* Chronic pulmonary diseases\n* Ischemic heart diseases","FEMALE","35 Years",{"count":147,"type":20},160,"Urinary tract infections (UTIs) are a major clinical issue, especially in pregnant women, due to physiological changes that increase susceptibility. If untreated, UTIs can lead to severe complications like preterm labor and low birth weight. Preeclampsia, a hypertensive disorder affecting 0.2-9.2% of pregnancies, is another leading cause of maternal and fetal complications. The relationship between UTIs and preeclampsia remains controversial, with some studies suggesting an association while others show conflicting results. Research gaps highlight the need for region-specific studies, particularly in Pakistan, where both conditions contribute significantly to maternal and neonatal morbidity.\n\nThis study aims to investigate the association between UTIs and preeclampsia in pregnant women in Pakistan. It will use a cohort design, enrolling 160 patients (80 with UTIs, 80 without) from the Obstetrics Department of PAF Hospital, Islamabad. Participants will be followed until delivery, with preeclampsia diagnosed based on blood pressure and proteinuria criteria. Data will be analyzed using SPSS to calculate relative risk (RR), with statistical significance set at RR \\>1 and p ≤ 0.05. The findings could help improve prenatal care and reduce adverse outcomes in high-risk populations.",[25,150],"Preeclampsia",[150,152,153,154],"Pregnancy","Urinary tract infection","Term Birth","2025-04-29",{"date":157,"type":30},"2025-05-08",{"date":159,"type":30},"2025-01-01",{"date":161,"type":20},"2025-04-30",{"name":163,"class":37},"Pakistan Air Force (PAF) Hospital Islamabad",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":144,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":93,"phases":174,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":186,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":38},"100589350","phase-4-methenamine-hippurate-following-intradetrusor-onabotulinumtoxina-injection-100589350","NCT06953271","Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection","Methenamine Hippurate Compared to Typical Antibiotic Prophylaxis in the Prevention of Urinary Tract Infection Following Intradetrusor OnabotulinumtoxinA Injection for Treatment of Overactive Bladder: a Randomized Controlled Non-Inferiority Trial","META","Inclusion Criteria:\n\n* 18 years of age or older\n* undergoing intradetrusor BOTOX-A injections in the office setting for overactive bladder\n\nExclusion Criteria:\n\n* cisgender male individuals\n* neurogenic reasons for bladder symptoms (i.e. spinal cord injury, multiple sclerosis, etc.)\n* known allergy and\u002For contraindication to methenamine hippurate\n* currently already taking methenamine hippurate at the time of the procedure\n* taking antibiotics for any reason on the day of their BOTOX-A procedure\n* positive UTI at time of procedure (positive dip at time of procedure)\n* history of bladder cancer\n* history of pelvic radiation\n* surgically altered detrusor muscle\n* pre-procedural need for catheterization\n* diagnosis of Interstitial Cystitis\u002FPainful Bladder Syndrome (IC\u002FPBS)\n* pregnant or lactating individuals",{"count":173,"type":20},164,[175],"PHASE4","The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis medications. The primary outcome measure will be urinary tract infection (UTI) rates within 30 days from the BOTOX-A procedure. Secondary outcomes will assess patient satisfaction with the two post-procedural prophylaxis medications.",[178,25],"Overactive Bladder (OAB)",[180,181,182,120,183,184,185],"Overactive Bladder","onabotulinumtoxinA","Methenamine","BOTOX-A","UTI","OAB","NOT_YET_RECRUITING","2025-04-23",{"date":189,"type":30},"2025-05-01",{"date":191,"type":20},"2025-05-15",{"date":193,"type":20},"2027-01-01",{"name":195,"class":37},"Women and Infants Hospital of Rhode Island",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":144,"minAge":17,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":222},"100564138","rapid-point-of-care-bacteriuria-and-microbial-susceptibility-for-women-with-suspected-uncomplicated-urinary-tract-infections-diagnostic-accuracy-in-general-practice-100564138","NCT06625268","Rapid Point-of-care Bacteriuria and Microbial Susceptibility for Women With Suspected Uncomplicated Urinary Tract Infections: Diagnostic Accuracy in General Practice.","Machbarkeit Und Explorative Validierung Des PA-100-AST-Systems Bei Frauen Mit Verdacht Auf Eine Unkomplizierte Harnwergsinfektion in Der Hausarztpraxis - Eine Pilotstudie","Inclusion Criteria:\n\n* Female sex\n* Age 18 or older\n* Clinically suspected UTI according to the general practitioner\n\nExclusion Criteria:\n\n* Urinary catheter\n* Severe urinary tract abnormality (such as cancer or strictures)\n* Immunosuppression (such as chronic immunosuppressant use or AIDS)\n* Dementia or any other condition (including insufficient knowledge of the German language) that could affect informed consent\n* Known pregnancy",{"count":204,"type":20},200,"In this study, adult women presenting at their general practitioner with a likely bladder infection (with symptoms like a burning sensation when urinating, pain in the lower abdomen, and frequent or urgent need to urinate) will be invited. After informed consent, women provide a urine sample, which is tested using a new system called the PA-100-AST (from the manufacturer Sysmex). This point-of-care test showed first evidence to be able to quickly detect the presence of bacteria commonly responsible for bladder infections. If bacteria are found, the test also checks which antibiotics may work best to treat the infection. Additionally, a sample of the urine is sent to a lab for a traditional culture test, which is considered the most accurate method. The goal of this study is to compare the accuracy of the PA-100-AST system to the lab-based test to see how well it works in general practice.",[25],[208,209,210,211,212,213],"urinary tract infection","women","general practice","diagnosis","primary care","point-of-care test","2025-02-12",{"date":216,"type":30},"2025-02-17",{"date":218,"type":30},"2024-08-01",{"date":161,"type":20},{"name":221,"class":37},"Wuerzburg University Hospital",2,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":15,"sex":144,"minAge":17,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":93,"phases":233,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":38},"100578391","is-methenamine-prophylaxis-for-urinary-tract-infection-after-midurethral-sling-as-effective-as-antibiotic-prophylaxis-100578391","NCT06810687","Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?","Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis? A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female\n2. Age ≥ 18\n3. Patients undergoing mid-urethral sling procedure\n\nExclusion Criteria:\n\n1. Medication intolerance or allergy to study medications\n2. Renal impairment with GFR \\\u003C30\n3. Breast feeding\n4. Pregnancy\n5. Recurrent urinary tract infections\n6. Active urinary tract infection\n7. Immunosuppressive disease\n8. Interstitial cystitis","100 Years",{"count":232,"type":20},190,[234],"NA","Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%.\n\nPost-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI.\n\nThe investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.",[25],[208,238,239,240],"midurethral sling","prophylaxis","methenamine","2025-02-05",{"date":243,"type":30},"2025-02-07",{"date":245,"type":30},"2025-01-30",{"date":247,"type":20},"2028-01-30",{"name":249,"class":37},"Atlantic Health System",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":16,"minAge":115,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":259,"conditions":260,"keywords":261,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":38},"100563019","improving-urinary-tract-infection-diagnosis-in-older-patients-validation-of-a-biomarker-panel-uti-gold-100563019","NCT06610721","'Improving Urinary Tract Infection Diagnosis in Older Patients: Validation of a Biomarker Panel (UTI-GOLD)'","UTI-GOLD","Inclusion criteria:\n\n* Age 65 years or older\n* Clinically suspected UTI by treating physician\n* Sufficient understanding of the Dutch language\n\nExclusion criteria:\n\n* Inability to obtain urine\n* Inability to provide written consent\n* The presence of an indwelling catheter",{"count":258,"type":20},264,"The goal of this study is to improve the diagnosis of urinary tract infections (UTI) in older people (≥65 years). The main research questions are:\n\nResearch questions\n\n* What is the optimal cut-off for each individual biomarker NGAL,IL-6,AZU,TIMP2 and CXCL9 and associated, sensitivity, specificity, negative and positive predictive value.\n* sensitivity, specificity, negative and positive predictive value of a urine leukocyte count cut-off of 200 cells\u002FmicroL (validation)\n* What is the optimal combination of biomarkers for UTI diagnosis in older patients\n* As a secondary objective this study aims to evaluate the association between the levels of individual biomarker levels and 1) duration of symptoms 2) complications, 3) recurrence of UTI within 2 months, and length of hospital stay. Next to this, the performance of the astrego PA100 will be validated in diagnosing bacteriuria.\n\nParticipants will:\n\n* be asked to provide a urine sample once at the beginning of the study\n* be asked to answer some questions about their symptoms and overall health at the beginning of the study and after 8 weeks\n* have their vital parameters (temperature and blood pressure) measured once at the beginning of the study",[25],[153,262],"Biomarkers","2024-09-23",{"date":265,"type":30},"2024-09-24",{"date":267,"type":30},"2024-08-20",{"date":269,"type":20},"2026-10-15",{"name":271,"class":37},"Leiden University Medical Center"]